As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US Food and Drug Administration (FDA) for the randomised US Phase II trial of oral small molecule ...